Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by Baker BROS. Advisors LP

Baker BROS. Advisors LP trimmed its holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 11.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 4,345,736 shares of the company’s stock after selling 570,359 shares during the quarter. Baker BROS. Advisors LP owned approximately 0.07% of Monte Rosa Therapeutics worth $68,141,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GLUE. GAMMA Investing LLC acquired a new stake in shares of Monte Rosa Therapeutics in the fourth quarter valued at about $30,000. Russell Investments Group Ltd. acquired a new stake in Monte Rosa Therapeutics during the third quarter worth about $32,000. Lazard Asset Management LLC increased its position in Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after purchasing an additional 3,262 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares during the last quarter. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Price Performance

Shares of GLUE opened at $18.41 on Thursday. Monte Rosa Therapeutics, Inc. has a 1-year low of $4.12 and a 1-year high of $25.77. The stock has a market cap of $1.56 billion, a PE ratio of -12.44 and a beta of 1.60. The firm has a 50-day simple moving average of $18.60 and a two-hundred day simple moving average of $18.47.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. As a group, sell-side analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Insider Transactions at Monte Rosa Therapeutics

In other news, insider Philip Nickson sold 5,845 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $17.69, for a total value of $103,398.05. Following the completion of the transaction, the insider owned 55,000 shares of the company’s stock, valued at approximately $972,950. This trade represents a 9.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Jennifer Champoux sold 2,175 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the transaction, the chief operating officer directly owned 62,371 shares of the company’s stock, valued at approximately $1,247,420. The trade was a 3.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 6.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on GLUE shares. JPMorgan Chase & Co. raised their price objective on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Guggenheim cut their price objective on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Monte Rosa Therapeutics has an average rating of “Moderate Buy” and an average target price of $32.50.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.